Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 known ✓ | O00444 | 1/20 | 0.48 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.48 |
| ▸ | ERBB4 known ✓ | Q15303 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 20/20 | 0.53 |
| ▸ | SRC | P12931 | 12/20 | 0.53 |
| ▸ | TEK | Q02763 | 10/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.50 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL4823004 | 1.00 | LCK (0.53) | LCKSRCTEKKDRLIMK1 | |
| Fumaric Acid SCHEMBL4823009 | 1.00 | LCK (0.53) | LCKSRCTEKKDRLIMK1 | |
| Fumaric Acid SCHEMBL7704013 | 0.92 | LCK (0.49) | LCKSRCTEKKDRLIMK1 | |
| Fumaric Acid SCHEMBL6434226 | 0.87 | LCK (0.59) | LCKSRCTEKKDRLIMK1 | |
| Maleic Acid SCHEMBL6434220 | 0.87 | LCK (0.59) | LCKSRCTEKKDRLIMK1 | |
| Maleic Acid SCHEMBL6431001 | 0.87 | LCK (0.59) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6435215 | 0.85 | LCK (0.57) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL4827920 | 0.85 | LCK (0.69) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL4827919 | 0.85 | LCK (0.69) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL4823873 | 0.83 | LCK (0.63) | LCKSRCTEKKDRLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | PLK4 1922/4885EGFR 818/4885ERBB2 894/4885 |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | PLK4 1437/4885EGFR 1992/4885ERBB2 682/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | PLK4 1061/4885EGFR 2229/4885ERBB2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.